Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The STEP trials (Semaglutide Treatment Effect in People with obesity) showed that semaglutide reduced body weight by 15-22% compared to placebo over 68 weeks in people without diabetes
FACTORS THAT REDUCE GLP-1 SECRETION High-sugar, low-fiber diets Sedentary behavior Dysbiosis (imbalanced gut flora) Chronic inflammation REFERENCES 1
A newer drug of this class is semaglutide (sold under the brand name Wegovy), which was approved in 2021 and was found, on average, to reduce weight by 15% in one clinical trial where people took the drug for 68 weeks
Corticotropin-releasing hormone and the sympathoadrenal system are major mediators in the effects of peripherally administered Exendin-4 on the Hypothalamic-Pituitary-Adrenal axis of male rats
The evidence supporting GLP-1 medications for weight loss and metabolic health is robust
US$ 20.01
US$ 26.65
US$ 29.88
